Endocrinol Metab.  2016 Mar;31(1):120-126. 10.3803/EnM.2016.31.1.120.

Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome

• Lee HS
• Jung CH
• Kim SR
• Jang HC
• Park CY
• PROPIT Study Team

• KMID: 2169702
• DOI: http://doi.org/10.3803/EnM.2016.31.1.120

Abstract

BACKGROUND
Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study.
METHODS
We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups: 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks.
RESULTS
Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P≤0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year.
CONCLUSION
Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.

Keyword

Apolipoprotein B-48; Lp-PLA2; Metabolic syndrome; Pitavastatin

MeSH Terms

1-Alkyl-2-acetylglycerophosphocholine Esterase*
Apolipoprotein B-48*
Apolipoproteins
Cardiovascular Diseases
Cholesterol
Cholesterol, LDL
Humans
Life Style
Lipoproteins
Prospective Studies*
1-Alkyl-2-acetylglycerophosphocholine Esterase
Apolipoprotein B-48
Apolipoproteins
Cholesterol
Cholesterol, LDL
Lipoproteins

Reference

1. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006; 119:812–819. PMID: 17000207.

2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56:1113–1132. PMID: 20863953.

3. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol. 2000; 86:412–416. PMID: 10946034.

4. Lundbye JB, Thompson PD. Statin use in the metabolic syndrome. Curr Atheroscler Rep. 2005; 7:17–21. PMID: 15683597.

5. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372:224–233. PMID: 18640459.

6. Nakamura T, Kugiyama K. Triglycerides and remnant particles as risk factors for coronary artery disease. Curr Atheroscler Rep. 2006; 8:107–110. PMID: 16510044.

7. Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord. 2003; 27:862–865. PMID: 12821974.

8. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26:2523–2529. PMID: 16960105.

9. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999; 274:7018–7024. PMID: 10066756.

10. Lp-PLA(2) Studies Collaboration. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375:1536–1544. PMID: 20435228.

11. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, et al. Lipoprotein-associated phospholipase A₂ activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009; 30:107–115. PMID: 19019993.

12. Hirschler V, Merono T, Maccallini G, Gomez Rosso L, Aranda C, Brites F. Association of lipoprotein-associated phospholipase A₂ activity with components of the metabolic syndrome in apparently healthy boys. Cardiovasc Hematol Agents Med Chem. 2011; 9:78–83. PMID: 21476960.

13. Choi SH, Lim S, Hong ES, Seo JA, Park CY, Noh JH, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf). 2015; 82:670–677. PMID: 25109606.

14. Choi SH, Kim DJ, Lee KE, Kim YM, Song YD, Kim HD, et al. Cut-off value of waist circumference for metabolic syndrome patients in Korean adult population. J Korean Soc Study Obes. 2004; 13:53–60.

15. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997; 100:1166–1173. PMID: 9303923.

16. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123:2292–2333. PMID: 21502576.

17. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 2002; 277:31646–31655. PMID: 12070142.

18. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis. 2007; 190:282–290. PMID: 16624317.

19. Sato I, Ishikawa Y, Ishimoto A, Katsura S, Toyokawa A, Hayashi F, et al. Significance of measuring serum concentrations of remnant lipoproteins and apolipoprotein B-48 in fasting period. J Atheroscler Thromb. 2009; 16:12–20. PMID: 19262003.

20. Mori K, Ishida T, Yasuda T, Monguchi T, Sasaki M, Kondo K, et al. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin Chim Acta. 2013; 421:51–56. PMID: 23428589.

21. Varbo A, Benn M, Tybjærg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61:427–436. PMID: 23265341.

22. Dane-Stewart CA, Watts GF, Pal S, Chan D, Thompson P, Hung J, et al. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 2003; 52:1279–1286. PMID: 14564679.

23. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res. 2007; 48:1746–1753. PMID: 17526934.

24. Otokozawa S, Ai M, Diffenderfer MR, Asztalos BF, Tanaka A, Lamon-Fava S, et al. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism. 2009; 58:1536–1542. PMID: 19592048.

25. Racherla S, Arora R. Utility of Lp-PLA₂ in lipid-lowering therapy. Am J Ther. 2012; 19:115–120. PMID: 20634673.

26. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009; 20:415–420. PMID: 19667981.

27. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A₂ as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343:1148–1155. PMID: 11036120.

28. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005; 111:980–987. PMID: 15710755.

29. Garcia-Garcia HM, Serruys PW. Phospholipase A₂ inhibitors. Curr Opin Lipidol. 2009; 20:327–332. PMID: 19550325.

30. Suckling KE. Phospholipase A₂ inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs. 2009; 18:1425–1430.

31. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004; 89:1153–1159. PMID: 15001601.

32. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A₂ in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005; 95:1025–1032. PMID: 15842965.

33. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008; 201:345–352. PMID: 18472103.

34. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010; 122:2183–2200. PMID: 21098459.